A humanized monoclonal antibody targeting Staphylococcus aureus.

Area of Science:

• Immunology
• Microbiology
• Pharmacology

Background:

• Staphylococcus aureus poses a significant threat, particularly methicillin-resistant S. aureus (MRSA).
• The Microbial Surface Components Recognizing Adhesive Matrix Molecules (MSCRAMM) protein ClfA is crucial for S. aureus adherence to host tissues.
• Targeting ClfA offers a potential therapeutic strategy against S. aureus infections.

Purpose of the Study:

• To characterize Aurexis (tefibazumab), a humanized monoclonal antibody targeting Staphylococcus aureus ClfA.
• To evaluate the in vitro and in vivo efficacy of Aurexis in preclinical models.
• To assess the safety and pharmacokinetics of Aurexis in a Phase I clinical study.

Main Methods:

• In vitro assays to assess Aurexis binding to ClfA and inhibition of fibrinogen binding.
• Opsonophagocytosis assays to evaluate the impact of Aurexis on bacterial clearance.
• In vivo studies using murine septicemia and rabbit infective endocarditis models to assess Aurexis protection against MRSA.
• Phase I clinical trial to evaluate safety and pharmacokinetics in human subjects.

Main Results:

• Aurexis demonstrated high affinity and specificity for S. aureus ClfA.
• Aurexis inhibited ClfA-mediated binding to human fibrinogen and enhanced opsonophagocytosis.
• A single dose of Aurexis provided significant protection in preclinical models of MRSA infection (septicemia and infective endocarditis).
• Phase I study indicated a favorable safety profile and acceptable pharmacokinetics for Aurexis.

Conclusions:

• Aurexis is a promising therapeutic candidate targeting a key virulence factor of S. aureus.
• Preclinical efficacy and initial human safety data support the continued development of Aurexis for treating S. aureus infections.
• Further clinical evaluation in Phase II studies is warranted.